Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in treatment‐naïve patients. We evaluated EFV400 and EFV600 pharmacokinetics (NONMEM v. 7.2), assessing patient demographics and genetic polymorphisms (CYP2B6, CYP2A6, CYP3A4, NR1I3) as covariates and explored relationships with efficacy (plasma HIV‐RNA (pVL) <200 copies/mL) and safety outcomes at 48 weeks in 606 randomized ENCORE1 patients (female = 32%, African = 37%, Asian = 33%; EFV400 = 311, EFV600 = 295). CYP2B6 516G>T/983T>C/CYP2A6*9B/*17 and weight were associated with efavirenz CL/F. Exposure was significantly lower for EFV400 (geometric mean ratio, GMR; 90% confidence interval, CI: 0.73 (0.68–0.78)) but 97% (EFV400) and 98% (EFV600) of evaluable pVL was <200 copies/mL at 48 weeks (P = 0.802). Four of 20 patients with mid‐dose concentrations <1.0 mg/L had pVL ≥200 copies/mL (EFV400 = 1; EFV600 = 3). Efavirenz exposure was similar between those with and without efavirenz‐related side effects (GMR; 90% CI: 0.95 (0.88–1.02)). HIV suppression was comparable between doses despite significantly lower EFV400 exposure. Comprehensive evaluation of efavirenz pharmacokinetics/pharmacodynamics revealed important limitations in the accepted threshold concentration.

[1]  H. Jessen,et al.  Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Khoo,et al.  Pharmacogenetics of pregnancy‐induced changes in efavirenz pharmacokinetics , 2015, Clinical pharmacology and therapeutics.

[3]  A. Owen,et al.  CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients , 2014, Therapeutic drug monitoring.

[4]  S. Khoo,et al.  CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. , 2014, Pharmacogenetics & Genomics.

[5]  N. Ford,et al.  Does pregnancy affect the pharmacokinetics of efavirenz? , 2014, AIDS.

[6]  A. Matteelli,et al.  Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins , 2014, Clinical Pharmacokinetics.

[7]  B. Gazzard,et al.  Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial , 2014, The Lancet.

[8]  A. Winston,et al.  Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial , 2014, Journal of the International AIDS Society.

[9]  N. Sewankambo,et al.  Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes , 2014, PloS one.

[10]  G. Maartens,et al.  Neuronal toxicity of efavirenz: a systematic review , 2013, Expert opinion on drug safety.

[11]  C. Sukasem,et al.  Would a CYP2B6 test help HIV patients being treated with efavirenz? , 2013, Pharmacogenomics.

[12]  D. Havlir,et al.  Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Owen,et al.  Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor , 2013, Therapeutic drug monitoring.

[14]  A. Hill.  Optimizing HIV treatment , 2013, Current opinion in HIV and AIDS.

[15]  Gundo Weiler,et al.  Global Update on HIV Treatment 2013: Results, Impact and Opportunities , 2013 .

[16]  Marylyn D Ritchie,et al.  Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants , 2012, Pharmacogenetics and genomics.

[17]  J. McArthur,et al.  Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz , 2012, Journal of Pharmacology and Experimental Therapeutics.

[18]  R. Ramesar,et al.  PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients , 2012, BMC Medical Genetics.

[19]  C. Marzolini,et al.  Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model , 2012, Clinical pharmacology and therapeutics.

[20]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[21]  T. Harrer,et al.  Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. , 2011, The Journal of antimicrobial chemotherapy.

[22]  H. Goforth,et al.  A Systematic Review of the Psychiatric Side-Effects of Efavirenz , 2011, AIDS and Behavior.

[23]  Matthias Cavassini,et al.  Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. , 2011, The Journal of infectious diseases.

[24]  A. Amara.  Development and validation of a HPLC-MS/MS assay to quantify the anti-retroviral (ARV) drug, efavirenz and its major metabolites in plasma , 2011 .

[25]  L. Milani,et al.  A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. , 2009, British journal of clinical pharmacology.

[26]  A. Telenti,et al.  Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals , 2009, Clinical pharmacology and therapeutics.

[27]  Huldrych F. Günthard,et al.  In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function , 2009, Pharmacogenetics and genomics.

[28]  K. Sagoe,et al.  CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. , 2009, British journal of clinical pharmacology.

[29]  T. Harrer,et al.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. , 2008, The Journal of antimicrobial chemotherapy.

[30]  Prosper Chonzi,et al.  High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.

[31]  S. Matsushita,et al.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Urso FORTE. Urso.  HIGHLIGHTS OF PRESCRIBING INFORMATION , 2007 .

[33]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[34]  S. Khoo,et al.  Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals , 2006, Clinical pharmacokinetics.

[35]  F. Gutiérrez,et al.  Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  K. Tashima,et al.  Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals , 2005, Annals of Internal Medicine.

[37]  Amalio Telenti,et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.

[38]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[39]  L L Lumsden,et al.  PUBLIC HEALTH PERSPECTIVE. , 1919, American journal of public health.